Literature DB >> 22555153

Involvement of PTPN5, the gene encoding the striatal-enriched protein tyrosine phosphatase, in schizophrenia and cognition.

Ilana Pelov1, Omri Teltsh, Lior Greenbaum, Amihai Rigbi, Kyra Kanyas-Sarner, Bernard Lerer, Paul Lombroso, Yoav Kohn.   

Abstract

OBJECTIVE: Striatal-enriched protein tyrosine phosphatase (STEP) is a brain-specific member of the protein tyrosine phosphatase (PTP) family that has been implicated in learning and memory. In this study, we examined the association of the protein tyrosine phosphatase non-receptor 5 (PTPN5) gene, which encodes for STEP, with both schizophrenia and cognitive functioning in the Israeli Jewish population.
METHODS: A schizophrenia (SZ) case-control study of 868 participants was carried out (286 patients and 582 controls). Eleven PTPN5 tagging single-nucleotide polymorphisms (SNPs) were selected and single markers and haplotype association analyses were carried out. A cognitive variability study included 437 healthy women who completed a computerized cognitive battery. We performed univariate associations between the SNPs and cognitive performance. The possible functional role of these variants was examined by studying their association with gene expression levels in the brain.
RESULTS: In the SZ study, we found a nominal association in the whole sample between rs4075664 and SZ. Male patients with SZ showed a more significant association for three SNPs (rs4075664, rs2278732, and rs4757710). Haplotypes of the studied SNPs were associated with SZ both in the overall sample and within the male subsample. Expression analysis provided some support for the effects of the associated SNPs on PTPN5 expression level. The cognitive variability study showed positive associations between PTPN5 SNPs and different cognitive subtests. Principal component analysis showed an 'attention index' neurocognitive component that was associated with two SNP pairs (rs10832983 × rs10766504 and rs7932938 × rs4757718).
CONCLUSION: The results imply a model in which PTPN5 may play a role in normal cognitive functioning and contribute to aspects of the neuropathology of SZ.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22555153      PMCID: PMC3760343          DOI: 10.1097/YPG.0b013e3283518586

Source DB:  PubMed          Journal:  Psychiatr Genet        ISSN: 0955-8829            Impact factor:   2.458


  72 in total

1.  Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61.

Authors:  Pradeep Kurup; Yongfang Zhang; Jian Xu; Deepa V Venkitaramani; Vahram Haroutunian; Paul Greengard; Angus C Nairn; Paul J Lombroso
Journal:  J Neurosci       Date:  2010-04-28       Impact factor: 6.167

Review 2.  Age at onset and cognition in schizophrenia: meta-analysis.

Authors:  T K Rajji; Z Ismail; B H Mulsant
Journal:  Br J Psychiatry       Date:  2009-10       Impact factor: 9.319

Review 3.  The role of genetics in the etiology of schizophrenia.

Authors:  Pablo V Gejman; Alan R Sanders; Jubao Duan
Journal:  Psychiatr Clin North Am       Date:  2010-03

4.  Common variants on chromosome 6p22.1 are associated with schizophrenia.

Authors:  Jianxin Shi; Douglas F Levinson; Jubao Duan; Alan R Sanders; Yonglan Zheng; Itsik Pe'er; Frank Dudbridge; Peter A Holmans; Alice S Whittemore; Bryan J Mowry; Ann Olincy; Farooq Amin; C Robert Cloninger; Jeremy M Silverman; Nancy G Buccola; William F Byerley; Donald W Black; Raymond R Crowe; Jorge R Oksenberg; Daniel B Mirel; Kenneth S Kendler; Robert Freedman; Pablo V Gejman
Journal:  Nature       Date:  2009-07-01       Impact factor: 49.962

Review 5.  Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?

Authors:  Gerard J Marek; Berthold Behl; Anton Y Bespalov; Gerhard Gross; Younglim Lee; Hans Schoemaker
Journal:  Mol Pharmacol       Date:  2009-11-23       Impact factor: 4.436

Review 6.  Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications.

Authors:  Pablo A Gaspar; M Leonor Bustamante; Hernán Silva; Francisco Aboitiz
Journal:  J Neurochem       Date:  2009-08-04       Impact factor: 5.372

Review 7.  New findings in the genetics of major psychoses.

Authors:  Markus M Nöthen; Vanessa Nieratschker; Sven Cichon; Marcella Rietschel
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

8.  Microduplications of 16p11.2 are associated with schizophrenia.

Authors:  Shane E McCarthy; Vladimir Makarov; George Kirov; Anjene M Addington; Jon McClellan; Seungtai Yoon; Diana O Perkins; Diane E Dickel; Mary Kusenda; Olga Krastoshevsky; Verena Krause; Ravinesh A Kumar; Detelina Grozeva; Dheeraj Malhotra; Tom Walsh; Elaine H Zackai; Paige Kaplan; Jaya Ganesh; Ian D Krantz; Nancy B Spinner; Patricia Roccanova; Abhishek Bhandari; Kevin Pavon; B Lakshmi; Anthony Leotta; Jude Kendall; Yoon-Ha Lee; Vladimir Vacic; Sydney Gary; Lilia M Iakoucheva; Timothy J Crow; Susan L Christian; Jeffrey A Lieberman; T Scott Stroup; Terho Lehtimäki; Kaija Puura; Chad Haldeman-Englert; Justin Pearl; Meredith Goodell; Virginia L Willour; Pamela Derosse; Jo Steele; Layla Kassem; Jessica Wolff; Nisha Chitkara; Francis J McMahon; Anil K Malhotra; James B Potash; Thomas G Schulze; Markus M Nöthen; Sven Cichon; Marcella Rietschel; Ellen Leibenluft; Vlad Kustanovich; Clara M Lajonchere; James S Sutcliffe; David Skuse; Michael Gill; Louise Gallagher; Nancy R Mendell; Nick Craddock; Michael J Owen; Michael C O'Donovan; Tamim H Shaikh; Ezra Susser; Lynn E Delisi; Patrick F Sullivan; Curtis K Deutsch; Judith Rapoport; Deborah L Levy; Mary-Claire King; Jonathan Sebat
Journal:  Nat Genet       Date:  2009-10-25       Impact factor: 38.330

9.  Common polygenic variation contributes to risk of schizophrenia and bipolar disorder.

Authors:  Shaun M Purcell; Naomi R Wray; Jennifer L Stone; Peter M Visscher; Michael C O'Donovan; Patrick F Sullivan; Pamela Sklar
Journal:  Nature       Date:  2009-07-01       Impact factor: 49.962

10.  Common variants conferring risk of schizophrenia.

Authors:  Hreinn Stefansson; Roel A Ophoff; Stacy Steinberg; Ole A Andreassen; Sven Cichon; Dan Rujescu; Thomas Werge; Olli P H Pietiläinen; Ole Mors; Preben B Mortensen; Engilbert Sigurdsson; Omar Gustafsson; Mette Nyegaard; Annamari Tuulio-Henriksson; Andres Ingason; Thomas Hansen; Jaana Suvisaari; Jouko Lonnqvist; Tiina Paunio; Anders D Børglum; Annette Hartmann; Anders Fink-Jensen; Merete Nordentoft; David Hougaard; Bent Norgaard-Pedersen; Yvonne Böttcher; Jes Olesen; René Breuer; Hans-Jürgen Möller; Ina Giegling; Henrik B Rasmussen; Sally Timm; Manuel Mattheisen; István Bitter; János M Réthelyi; Brynja B Magnusdottir; Thordur Sigmundsson; Pall Olason; Gisli Masson; Jeffrey R Gulcher; Magnus Haraldsson; Ragnheidur Fossdal; Thorgeir E Thorgeirsson; Unnur Thorsteinsdottir; Mirella Ruggeri; Sarah Tosato; Barbara Franke; Eric Strengman; Lambertus A Kiemeney; Ingrid Melle; Srdjan Djurovic; Lilia Abramova; Vasily Kaleda; Julio Sanjuan; Rosa de Frutos; Elvira Bramon; Evangelos Vassos; Gillian Fraser; Ulrich Ettinger; Marco Picchioni; Nicholas Walker; Timi Toulopoulou; Anna C Need; Dongliang Ge; Joeng Lim Yoon; Kevin V Shianna; Nelson B Freimer; Rita M Cantor; Robin Murray; Augustine Kong; Vera Golimbet; Angel Carracedo; Celso Arango; Javier Costas; Erik G Jönsson; Lars Terenius; Ingrid Agartz; Hannes Petursson; Markus M Nöthen; Marcella Rietschel; Paul M Matthews; Pierandrea Muglia; Leena Peltonen; David St Clair; David B Goldstein; Kari Stefansson; David A Collier
Journal:  Nature       Date:  2009-07-01       Impact factor: 49.962

View more
  3 in total

1.  Protein expression of targets of the FMRP regulon is altered in brains of subjects with schizophrenia and mood disorders.

Authors:  Timothy D Folsom; Paul D Thuras; S Hossein Fatemi
Journal:  Schizophr Res       Date:  2015-05-05       Impact factor: 4.939

Review 2.  Disruption of striatal-enriched protein tyrosine phosphatase (STEP) function in neuropsychiatric disorders.

Authors:  Takatoshi Karasawa; Paul J Lombroso
Journal:  Neurosci Res       Date:  2014-09-10       Impact factor: 3.304

3.  Inhibition of the tyrosine phosphatase STEP61 restores BDNF expression and reverses motor and cognitive deficits in phencyclidine-treated mice.

Authors:  Jian Xu; Pradeep Kurup; Tyler D Baguley; Ethan Foscue; Jonathan A Ellman; Angus C Nairn; Paul J Lombroso
Journal:  Cell Mol Life Sci       Date:  2015-10-08       Impact factor: 9.261

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.